Nutra Pharma Corp (NPHC) Non-Current Debt (2010 - 2026)

Nutra Pharma has disclosed Non-Current Debt across 16 years of filings, most recently posting $134808.0 for Q2 2026.

• In Q2 2026, Non-Current Debt fell 2.63% year-over-year to $134808.0; the TTM figure through Jun 2026 stood at $134808.0 (down 2.63% YoY), while the FY2025 annual figure was $136644.0, down 2.55% from the prior year.
• Non-Current Debt came in at $134808.0 for Q2 2026 at Nutra Pharma, down from $135730.0 in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $8.5 million in Q4 2023 to a low of $134808.0 in Q2 2026.
• Average Non-Current Debt over 5 years is $3.2 million, with a median of $1.3 million recorded in 2022.
• Year-over-year, Non-Current Debt surged 565.76% in 2022 and sank 98.36% in 2025.
• Over 5 years, Non-Current Debt stood at $1.3 million in 2022, then soared by 537.21% to $8.5 million in 2023, then tumbled by 98.34% to $140217.0 in 2024, then declined by 2.55% to $136644.0 in 2025, then slipped by 1.34% to $134808.0 in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $134808.0 in Q2 2026, $135730.0 in Q1 2026, and $136644.0 in Q4 2025.